# Case Timeline

## Historical Background

| Date | Event |
|------|-------|
| 2010 | First diagnosis of right-sided breast cancer; surgery and radiation by Gerald Gui |
| 2015 | Mastectomy due to radiation scarring |
| 2019 | Metastatic disease diagnosed |
| March 2025 | Last PET scan before July 2025 |

## 2025 - Final Months

### July 2025 - London Treatment

| Date | Event | Invoice |
|------|-------|---------|
| July 10, 2025 | Prof. Justin Stebbing consultation via Zoom (patient in Malta) | - |
| July 10, 2025 | Prof. Stebbing letter to Dr. Laporta re: Louise Stoten | - |
| July 10, 2025 | Prof. Stebbing "To Whom It May Concern" letter confirming <12 month prognosis | - |
| July 11, 2025 | London: Administration fee + Zometa 4mg | INV-0167 (£192.65) |
| July 11, 2025 | London: Blood Tests | INV-0176 (£1,737.00) |
| July 14, 2025 | London: IV infusion (Vit C, Marais, Meyers) | INV-0173 (£288.25) |
| July 15, 2025 | London: IV infusion + Ceftriaxone antibiotic + Endovascular laser | INV-0178 (£437.00) |
| July 30, 2025 | London: Consultation (15 min) | INV-0240 (£195.00) |
| July-August 2025 | **ALLEGED:** London clinic operating without CQC license | - |

### August 2025 - London to Cape Town Transfer

| Date | Event | Invoice |
|------|-------|---------|
| Aug 1, 2025 | London: IV infusion (Vit C, Glutathione, Marais, Meyers) | INV-0241 (£332.20) |
| Aug 4, 2025 | London: IV infusion + Hyperthermia 90min + **Prednisolone 5mg** | INV-0243 (£1,037.15) |
| Aug 4, 2025 | London: Consultation (15 min) | INV-0244 (£195.00) |
| ~Aug 5-7, 2025 | Patient travels to Cape Town | - |
| **ALLEGED:** | London clinic - medication overdose incident (steroids) | - |

### August 2025 - Sanctura Cape Town Treatment

| Date | Event | Invoice Total |
|------|-------|---------------|
| Aug 8, 2025 | IV infusion treatment (Vitamin C, Meyers Cocktail, Glutathione, etc.) | R 2,778.71 |
| Aug 8, 2025 | Azithromycin 500mg prescribed | R 183.60 |
| Aug 10, 2025 | Targinact prescribed | R 657.36 |
| Aug 11, 2025 | **First Eribulin (Halaven) chemotherapy** + Facility fee | R 19,080.82 |
| Aug 11, 2025 | Hyperthermia 90 minutes | R 5,333.77 |
| Aug 11-12, 2025 | Supportive meds (Movicol, Ondansetron, Emend) | R 1,143.44 |
| Aug 13, 2025 | Hyperthermia sessions (90 min + 60 min) | R 8,889.62 |
| Aug 13, 2025 | Consultation + IV treatment + Zometa + Invanz | R 4,724.27 |
| Aug 14, 2025 | IV treatment + Invanz | R 2,318.14 |
| Aug 15, 2025 | IV treatment + Invanz + Furosemide | R 2,323.48 |
| Aug 16, 2025 | IV treatment + Invanz + Furosemide | R 2,323.48 |
| Aug 17, 2025 | IV treatment + Invanz + Furosemide | R 2,323.48 |
| Aug 18, 2025 | IV treatment + Invanz | R 2,318.14 |
| Aug 19, 2025 | IV treatment + Invanz + Neupogen | R 3,373.41 |
| Aug 20, 2025 | IV treatment + Invanz + Neupogen | R 3,373.41 |
| Aug 21, 2025 | Neupogen | R 1,055.27 |
| Aug 22, 2025 | Consultation + Facility fee + Neupogen + Blood admin | R 7,484.66 |
| Aug 25, 2025 | Facility fee + Blood admin | R 2,676.40 |
| Aug 28, 2025 | Consultation | R 1,919.50 |

### September 2025 - Final Treatment & Decline

| Date | Event | Invoice Total |
|------|-------|---------------|
| Sept 1, 2025 | **Second Eribulin (Halaven) chemotherapy** + Hyperthermia | R 16,189.80 |
| Sept 5, 2025 | Nplate (platelet support) | R 11,534.92 |
| Sept 9, 2025 | IV Invanz + Neupogen + call out fee | R 4,271.71 |
| Sept 10, 2025 | IV Invanz + call out fee | R 2,849.01 |
| Sept 11, 2025 | IV Invanz + Doctrim + call out fee | R 2,939.81 |
| Sept 12, 2025 | IV treatment + Invanz + Vitamin C cocktail + supplements | R 4,703.75 |
| Sept 13, 2025 | IV Invanz + call out fee | R 2,849.01 |
| Sept 14, 2025 | IV Invanz + call out fee | R 2,849.01 |
| Sept 15, 2025 | **Referral letter to Dr. Roger de Andrade** | - |
| Sept 15, 2025 | IV Invanz (final Sanctura treatment) | R 2,349.01 |
| Sept 15, 2025 | Patient admitted to Dr. de Andrade at Cape Gate Hospital | - |
| **Sept 16, 2025** | **Louise Stoten dies at Cape Gate Hospital** | - |

### 2026 - Complaint

| Date | Event |
|------|-------|
| ~Feb 1, 2026 | Threatening message received from Paul Stoten |
| Feb 1, 2026 | CEO's initial response/direction memo |

## Key Clinical Notes

**September 15, 2025 Referral (Dr. Laporta to Dr. de Andrade):**
- Patient had "volatile inflammatory markers and hypoxic pneumonia"
- CRP spike following prolonged neutropenia
- 7 days of Ertapenem with partial response
- No benefit from Moxifloxacin
- Concern about Pneumocystis jirovecii pneumonia
- Alternative diagnosis: lymphangitic carcinomatosis progression
- CXR unchanged; CT showed further disease progression

**CEO Notes (Feb 2026):**
- Patient "left our clinic fairly stable but requiring ongoing oxygen"
- "Worsening respiratory symptoms at Cape Gate"
- "Either infection or tumor"
- "Very well managed"
